Michael Riebe

iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA.

American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC.

Research Triangle Institute is a non-profit organization which provides research and development services. It offers surveys and data collection, statistics and data science, assessment and analysis, program design and implementation, and research technologies and analytical laboratory. The company was founded in 1958 and is headquartered in Research Triangle Park, NC.

AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE.

Pearl Therapeutics, Inc. develops therapies for the treatment of chronic respiratory diseases. It offers respiratory product development, high quality therapies for COPD, Asthma and treatment and prevention of chronic respiratory diseases and asthma. The company was founded in 2006 by Sarvajna Dwivedi and is headquartered in Redwood City, CA.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC.